当前位置: 首页 >> 检索结果
241. Randomized Trial of Stand-Alone Use of the Antimicrobial Envelope in High-Risk Cardiac Device Patients.
作者: Christopher R Ellis.;Arnold J Greenspon.;John A Andriulli.;Paul A Gould.;Roger G Carillo.;Matthew J Kolek.;Rachel Donegan.;Ansel P Amaral.;Suneet Mittal.
来源: Circ Arrhythm Electrophysiol. 2023年16卷5期e011740页
Cardiac implantable electronic device (CIED) infection has a high mortality. Previous investigations showed reduced postoperative infections using skin preparation with chlorhexidine, preoperative intravenous antibiotics, and a TYRX-a antibacterial envelope. The additional benefit of antibiotic pocket wash and postoperative antibiotics has not been systematically studied.
242. Effectiveness of the Family Heart Talk Communication Tool in Improving Family Member Screening for Dilated Cardiomyopathy: Results of a Randomized Trial.
作者: Daniel D Kinnamon.;Elizabeth Jordan.;Garrie J Haas.;Mark Hofmeyer.;Evan Kransdorf.;Gregory A Ewald.;Alanna A Morris.;Anjali Owens.;Brian Lowes.;Douglas Stoller.;W H Wilson Tang.;Sonia Garg.;Barry H Trachtenberg.;Palak Shah.;Salpy V Pamboukian.;Nancy K Sweitzer.;Matthew T Wheeler.;Jane E Wilcox.;Stuart Katz.;Stephen Pan.;Javier Jimenez.;Keith D Aaronson.;Daniel P Fishbein.;Frank Smart.;Jessica Wang.;Stephen S Gottlieb.;Daniel P Judge.;Charles K Moore.;Jonathan O Mead.;Gordon S Huggins.;Hanyu Ni.;Wylie Burke.;Ray E Hershberger.; .
来源: Circulation. 2023年147卷17期1281-1290页
Managing disease risk among first-degree relatives of probands diagnosed with a heritable disease is central to precision medicine. A critical component is often clinical screening, which is particularly important for conditions like dilated cardiomyopathy (DCM) that remain asymptomatic until severe disease develops. Nonetheless, probands are frequently ill-equipped to disseminate genetic risk information that motivates at-risk relatives to complete recommended clinical screening. An easily implemented remedy for this key issue has been elusive.
243. Intracardiac Echocardiography-Guided Implantation for Proximal Left Bundle Branch Pacing.
作者: XiaoHui Kuang.;Xi Zhang.;YanJu Cui.;FeiYu Wei.;Peng Wu.;XiaoLong Gao.;Hong Xiang.;HaiYan Wu.;Li-Lin Wang.;Xiaohong Zhou.;Weijian Huang.;Jie Fan.
来源: Circ Arrhythm Electrophysiol. 2023年16卷4期e011408页
Multiple screw-in attempts under fluoroscopy are often needed to place the pacing lead tip near or at the left bundle branch (LBB). This study was conducted to evaluate the feasibility of implanting an LBB pacing lead in the proximal LBB (PLBB) guided by intracardiac echocardiography (ICE).
244. Comparison of 3- to 6-Month Versus 12-Month Dual Antiplatelet Therapy After Coronary Intervention Using the Contemporary Drug-Eluting Stents With Ultrathin Struts: The HOST-IDEA Randomized Clinical Trial.
作者: Jung-Kyu Han.;Doyeon Hwang.;Seokhun Yang.;Sang-Hyeon Park.;Jeehoon Kang.;Han-Mo Yang.;Kyung Woo Park.;Hyun-Jae Kang.;Bon-Kwon Koo.;Seung-Ho Hur.;Weon Kim.;Seok Yeon Kim.;Sang-Hyun Park.;Seung Hwan Han.;Sang-Hyun Kim.;Sanghoon Shin.;Yong Hoon Kim.;Kyungil Park.;Namho Lee.;Seung Jin Lee.;Jin Won Kim.;Hyo-Soo Kim.
来源: Circulation. 2023年147卷18期1358-1368页
Limited data are available on short-term dual antiplatelet therapy (DAPT) after percutaneous coronary intervention using third-generation drug-eluting stents with ultrathin struts and advanced polymer technology. We investigated whether 3- to 6-month DAPT was noninferior to 12-month DAPT after implantation of drug-eluting stents with ultrathin struts and advanced polymer technology.
245. Eliminating Medication Copayments for Low-Income Older Adults at High Cardiovascular Risk: A Randomized Controlled Trial.
作者: David J T Campbell.;Chad Mitchell.;Brenda R Hemmelgarn.;Marcello Tonelli.;Peter Faris.;Jianguo Zhang.;Ross T Tsuyuki.;Jane Fletcher.;Flora Au.;Scott Klarenbach.;Derek V Exner.;Braden J Manns.; .
来源: Circulation. 2023年147卷20期1505-1514页
One in eight people with heart disease has poor medication adherence that, in part, is related to copayment costs. This study tested whether eliminating copayments for high-value medications among low-income older adults at high cardiovascular risk would improve clinical outcomes.
246. Cluster Randomized Trial of a Personalized Clinical Decision Support Intervention to Improve Statin Prescribing in Patients With Atherosclerotic Cardiovascular Disease.
作者: Salim S Virani.;David J Ramsey.;Dax Westerman.;Mark K Kuebeler.;Liang Chen.;Julia M Akeroyd.;Glenn T Gobbel.;Christie M Ballantyne.;Laura A Petersen.;Alexander Turchin.;Michael E Matheny.
来源: Circulation. 2023年147卷18期1411-1413页 247. Effect of Electronic Nudges on Influenza Vaccination Rate in Older Adults With Cardiovascular Disease: Prespecified Analysis of the NUDGE-FLU Trial.
作者: Daniel Modin.;Niklas Dyrby Johansen.;Muthiah Vaduganathan.;Ankeet S Bhatt.;Simin Gharib Lee.;Brian L Claggett.;Erica L Dueger.;Sandrine I Samson.;Matthew M Loiacono.;Lars Køber.;Scott D Solomon.;Pradeesh Sivapalan.;Jens Ulrik Stæhr Jensen.;Cyril Jean-Marie Martel.;Palle Valentiner-Branth.;Tyra Grove Krause.;Tor Biering-Sørensen.
来源: Circulation. 2023年147卷18期1345-1354页
Influenza vaccines have been demonstrated to effectively reduce the incidence of influenza infection and potentially associated risks of cardiovascular events in patients with cardiovascular disease (CVD). Despite strong guideline and public health endorsements, global influenza vaccination rates in patients with CVD are highly variable. This prespecified analysis of NUDGE-FLU (Nationwide Utilization of Danish Government Electronic Letter System for Increasing Influenza Vaccine Uptake) examined the effect of digital behavioral nudges on influenza vaccine uptake based on the presence of CVD.
248. Self-Management Support Using Advertising Principles for Older Adults With Low Income at High Cardiovascular Risk: A Randomized Controlled Trial.
作者: David J T Campbell.;Marcello Tonelli.;Brenda R Hemmelgarn.;Peter Faris.;Jianguo Zhang.;Flora Au.;Ross T Tsuyuki.;Chad Mitchell.;Raj Pannu.;Tavis Campbell.;Noah Ivers.;Jane Fletcher.;Derek V Exner.;Braden J Manns.; .
来源: Circulation. 2023年147卷20期1492-1504页
Self-management education and support (SMES) interventions have modest effects on intermediate outcomes for those at risk of cardiovascular disease, but few studies have measured or demonstrated an effect on clinical end points. Advertising for commercial products is known to influence behavior, but advertising principles are not typically incorporated into SMES design.
249. On-Site Computed Tomography-Derived Fractional Flow Reserve to Guide Management of Patients With Stable Coronary Artery Disease: The TARGET Randomized Trial.
作者: Junjie Yang.;Dongkai Shan.;Xi Wang.;Xiaoqing Sun.;Meihua Shao.;Kan Wang.;Yueying Pan.;Zhiqiang Wang.;U Joseph Schoepf.;Rock H Savage.;Mei Zhang.;Mei Dong.;Lei Xu.;Yujie Zhou.;Xiang Ma.;Xinyang Hu.;Liming Xia.;Hesong Zeng.;Zinuan Liu.;Yundai Chen.
来源: Circulation. 2023年147卷18期1369-1381页
Computed tomography-derived fractional flow reserve (CT-FFR) using on-site machine learning enables identification of both the presence of coronary artery disease and vessel-specific ischemia. However, it is unclear whether on-site CT-FFR improves clinical or economic outcomes when compared with the standard of care in patients with stable coronary artery disease.
250. Prognostic Impact of Coronary Microvascular Dysfunction According to Different Patterns by Invasive Physiologic Indexes in Symptomatic Patients With Intermediate Coronary Stenosis.
作者: David Hong.;Doosup Shin.;Seung Hun Lee.;Hyun Sung Joh.;Ki Hong Choi.;Hyun Kuk Kim.;Sang Jin Ha.;Taek Kyu Park.;Jeong Hoon Yang.;Young Bin Song.;Joo-Yong Hahn.;Seung-Hyuk Choi.;Hyeon-Cheol Gwon.;Joo Myung Lee.
来源: Circ Cardiovasc Interv. 2023年16卷3期e012621页
Coronary microvascular dysfunction is a clinically significant component of ischemic heart disease. There can be heterogenous patterns of coronary microvascular dysfunction defined by invasive physiologic indexes such as coronary flow reserve (CFR) and index of microcirculatory resistance (IMR). We sought to compare the prognosis of coronary microvascular dysfunction according to different patterns of CFR and IMR.
251. Integrating Community Health Workers into Community-Based Primary Care Practice Settings to Improve Blood Pressure Control Among South Asian Immigrants in New York City: Results from a Randomized Control Trial.
作者: Nadia S Islam.;Laura C Wyatt.;Shahmir H Ali.;Jennifer M Zanowiak.;Sadia Mohaimin.;Keith Goldfeld.;Priscilla Lopez.;Rashi Kumar.;Susan Beane.;Lorna E Thorpe.;Chau Trinh-Shevrin.
来源: Circ Cardiovasc Qual Outcomes. 2023年16卷3期e009321页
Blood pressure (BP) control is suboptimal in minority communities, including Asian populations. We evaluate the feasibility, adoption, and effectiveness of an integrated CHW-led health coaching and practice-level intervention to improve hypertension control among South Asian patients in New York City, Project IMPACT (Integrating Million Hearts for Provider and Community Transformation). The primary outcome was BP control, and secondary outcomes were systolic BP and diastolic BP at 6-month follow-up.
252. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.
作者: Truman J Milling.;Saskia Middeldorp.;Lizhen Xu.;Bruce Koch.;Andrew Demchuk.;John W Eikelboom.;Peter Verhamme.;Alexander T Cohen.;Jan Beyer-Westendorf.;C Michael Gibson.;Jose Lopez-Sendon.;Mark Crowther.;Ashkan Shoamanesh.;Michiel Coppens.;Jeannot Schmidt.;Pierre Albaladejo.;Stuart J Connolly.; .
来源: Circulation. 2023年147卷13期1026-1038页
Andexanet alfa is a modified recombinant inactive factor Xa (FXa) designed to reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors) was a multicenter, prospective, phase-3b/4, single-group cohort study that evaluated andexanet alfa in patients with acute major bleeding. The results of the final analyses are presented.
253. Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial.
作者: Hertzel C Gerstein.;Zhuoru Li.;Chinthanie Ramasundarahettige.;Seungjae Baek.;Kelley R H Branch.;Stefano Del Prato.;Carolyn S P Lam.;Renato D Lopes.;Richard Pratley.;Julio Rosenstock.;Naveed Sattar.
来源: Circulation. 2023年147卷13期1004-1013页
In the AMPLITUDE-O (Effect of Efpeglenatide on Cardiovascular Outcomes) cardiovascular outcomes trial, adding either 4 mg or 6 mg weekly of the glucagon-like peptide-1 receptor agonist efpeglenatide to usual care reduced major adverse cardiovascular events (MACE) in people with type 2 diabetes at high cardiovascular risk. Whether these benefits are dose related remains uncertain.
254. Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE.
作者: Prakriti Gaba.;Michelle L O'Donoghue.;Jeong-Gun Park.;Stephen D Wiviott.;Dan Atar.;Julia F Kuder.;KyungAh Im.;Sabina A Murphy.;Gaetano M De Ferrari.;Zbigniew A Gaciong.;Kalman Toth.;Ioanna Gouni-Berthold.;Jose Lopez-Miranda.;François Schiele.;François Mach.;Jose H Flores-Arredondo.;J Antonio G López.;Mary Elliott-Davey.;Bei Wang.;Maria Laura Monsalvo.;Siddique Abbasi.;Robert P Giugliano.;Marc S Sabatine.
来源: Circulation. 2023年147卷16期1192-1203页
Low-density lipoprotein cholesterol (LDL-C) is a well-established risk factor for atherosclerotic cardiovascular disease. However, the optimal achieved LDL-C level with regard to efficacy and safety in the long term remains unknown.
255. Five-Year Clinical Outcome of the Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent Compared to the Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: From the SORT OUT VII Trial.
作者: Kirstine Nørregaard Hansen.;Lisette Okkels Jensen.;Michael Maeng.;Martin Kirk Christensen.;Manijeh Noori.;Johnny Kahlert.;Lars Jakobsen.;Anders Junker.;Phillip Freeman.;Julia Ellert-Gregersen.;Bent Raungaard.;Christian Juhl Terkelsen.;Karsten Tange Veien.;Evald Høj Christiansen.
来源: Circ Cardiovasc Interv. 2023年16卷1期e012332页
Biodegradable polymer drug-eluting stents were developed to improve safety and efficacy outcomes for patients undergoing percutaneous coronary intervention. However, few long-term follow-up efficacy studies are available. The study sought to investigate 5-year results from the SORT OUT VII trial (Scandinavian Organization for Randomized Trials With Clinical Outcome) comparing the biodegradable polymer ultrathin-strut sirolimus-eluting Orsiro stent (O-SES) versus the biodegradable polymer biolimus-eluting Nobori stent (N-BES).
256. Baseline Characteristics of Pediatric Patients With Heart Failure Due to Systemic Left Ventricular Systolic Dysfunction in the PANORAMA-HF Trial.
作者: Robert Shaddy.;Michael Burch.;Paul F Kantor.;Susan Solar-Yohay.;Tania Garito.;Sijia Zhang.;Michele Kocun.;Damien Bonnet.
来源: Circ Heart Fail. 2023年16卷3期e009816页
Sacubitril/valsartan has been approved for the management of heart failure (HF) with reduced ejection fraction in adults. PANORAMA-HF trial (Prospective Trial to Assess the Angiotensin Receptor Blocker Neprilysin Inhibitor LCZ696 Versus Angiotensin-Converting Enzyme Inhibitor for the Medical Treatment of Pediatric HF) investigated its effects on clinical outcomes in pediatric patients with HF.
257. Rehospitalization Events After Aortic Valve Replacement: Insights From the PARTNER Trial.
作者: Chetan P Huded.;Suzanne V Arnold.;Adnan K Chhatriwalla.;John T Saxon.;Samir Kapadia.;Xiao Yu.;John G Webb.;Vinod H Thourani.;Susheel K Kodali.;Craig R Smith.;Michael J Mack.;Martin B Leon.;David J Cohen.
来源: Circ Cardiovasc Interv. 2022年15卷12期e012195页
Rehospitalization is a common end point in clinical trials of structural heart interventions, but whether rehospitalization is clinically and prognostically relevant in these patients is uncertain. The aim of this study was to evaluate the risk of rehospitalization events after aortic valve replacement (AVR) and their association with mortality and health status.
258. Challenging the Hemodynamic Hypothesis in Heart Failure With Preserved Ejection Fraction: Is Exercise Capacity Limited by Elevated Pulmonary Capillary Wedge Pressure?
作者: Satyam Sarma.;James P MacNamara.;Bryce N Balmain.;Christopher M Hearon.;Denis J Wakeham.;Andrew R Tomlinson.;Linda S Hynan.;Tony G Babb.;Benjamin D Levine.
来源: Circulation. 2023年147卷5期378-387页
Exercise intolerance is a defining characteristic of heart failure with preserved ejection fraction (HFpEF). A marked rise in pulmonary capillary wedge pressure (PCWP) during exertion is pathognomonic for HFpEF and is thought to be a key cause of exercise intolerance. If true, acutely lowering PCWP should improve exercise capacity. To test this hypothesis, we evaluated peak exercise capacity with and without nitroglycerin to acutely lower PCWP during exercise in patients with HFpEF.
259. Gut Microbiota-Generated Phenylacetylglutamine and Heart Failure.
作者: Kymberleigh A Romano.;Ina Nemet.;Prasenjit Prasad Saha.;Arash Haghikia.;Xinmin S Li.;Maradumane L Mohan.;Beth Lovano.;Laurie Castel.;Marco Witkowski.;Jennifer A Buffa.;Yu Sun.;Lin Li.;Christopher M Menge.;Ilja Demuth.;Maximilian König.;Elisabeth Steinhagen-Thiessen.;Joseph A DiDonato.;Arjun Deb.;Fredrik Bäckhed.;W H Wilson Tang.;Sathyamangla Venkata Naga Prasad.;Ulf Landmesser.;David R Van Wagoner.;Stanley L Hazen.
来源: Circ Heart Fail. 2023年16卷1期e009972页
The gut microbiota-dependent metabolite phenylacetylgutamine (PAGln) is both associated with atherothrombotic heart disease in humans, and mechanistically linked to cardiovascular disease pathogenesis in animal models via modulation of adrenergic receptor signaling.
260. Efficacy and Safety of ARRY-371797 in LMNA-Related Dilated Cardiomyopathy: A Phase 2 Study.
作者: Calum A MacRae.;Matthew R G Taylor.;Luisa Mestroni.;John Moses.;Euan A Ashley.;Matthew T Wheeler.;Neal K Lakdawala.;Ray E Hershberger.;Victor Sandor.;Michael E Saunders.;Colleen Oliver.;Patrice A Lee.;Daniel P Judge.
来源: Circ Genom Precis Med. 2023年16卷1期e003730页
Lamin A/C gene (LMNA)-related dilated cardiomyopathy is a serious and life-threatening condition with a high unmet medical need. This phase 2 study assessed the effects of the oral selective p38 mitogen-activated protein kinase inhibitor ARRY-371797 on functional capacity and cardiac function in patients with LMNA-related dilated cardiomyopathy.
|